Virax Biolabs Stock Quote VRAX - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

0.7701

Bid

0.757

Ask

0.7701

Volume

25,585

0.759579 Day's Range 0.8446

0.759579 52 Week Range 8.9999

Market Cap

3.342M

Previous Close

0.82

Open

0.807

Last Trade

1165

0.7701

Last Trade Time

12:19:43

Financial Volume

$ 20,509

VWAP

0.80161

Average Volume (3m)

145,252

Shares Outstanding

4,340,000

Dividend Yield

PE Ratio

-0.52

Earnings Per Share (EPS)

-1.55

Revenue

156k

Net Profit

-6.73M

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases with a particular interest in the field of immunology. It is developing a proprietary T-Cell Test technology with the intention of providing an immunolo... Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases with a particular interest in the field of immunology. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. Show more

Sector

In Vitro,in Vivo Diagnostics

Industry

In Vitro,in Vivo Diagnostics

Website

viraxbiolabs.com

Headquarters

Oxon, Gbr

Founded

Virax Biolabs Group Ltd is listed in the In Vitro,in Vivo Diagnostics sector of the NASDAQ with ticker VRAX. The last closing price for Virax Biolabs was $0.82. Over the last year, Virax Biolabs shares have traded in a share price range of $ 0.759579 to $ 8.9999.

Virax Biolabs currently has 4,340,000 shares outstanding. The market capitalization of Virax Biolabs is $3.56 million. Virax Biolabs has a price to earnings ratio (PE ratio) of -0.52.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune...

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services...

Form S-8 - Securities to be offered to employees in employee benefit plans

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.1899	-19.78125	0.96	0.96	0.759579	51318	0.85528842	CS
4	-0.2299	-22.99	1	1.13	0.759579	46020	0.95918455	CS
12	-0.4599	-37.3902439024	1.23	1.34	0.759579	145252	1.06672863	CS
26	-1.0349	-57.3351800554	1.805	3.2	0.759579	223725	1.75284172	CS
52	-0.8899	-53.6084337349	1.66	8.9999	0.759579	1706320	4.03239809	CS
156	-199.2299	-99.61495	200	290	0.6	1313523	21.51102458	CS
260	-199.2299	-99.61495	200	290	0.6	1313523	21.51102458	CS

VRAX - Frequently Asked Questions (FAQ)

What is the current Virax Biolabs share price?

The current share price of Virax Biolabs is $ 0.7701

How many Virax Biolabs shares are in issue?

Virax Biolabs has 4,340,000 shares in issue

What is the market cap of Virax Biolabs?

The market capitalisation of Virax Biolabs is USD 3.56M

What is the 1 year trading range for Virax Biolabs share price?

Virax Biolabs has traded in the range of $ 0.759579 to $ 8.9999 during the past year

What is the PE ratio of Virax Biolabs?

The price to earnings ratio of Virax Biolabs is -0.52

What is the cash to sales ratio of Virax Biolabs?

The cash to sales ratio of Virax Biolabs is 22.28

What is the reporting currency for Virax Biolabs?

Virax Biolabs reports financial results in USD

What is the latest annual turnover for Virax Biolabs?

The latest annual turnover of Virax Biolabs is USD 156k

What is the latest annual profit for Virax Biolabs?

The latest annual profit of Virax Biolabs is USD -6.73M

What is the registered address of Virax Biolabs?

The registered address for Virax Biolabs is 30 BROADWICK STREET LONDON, W1F 8LX, OXON

What is the Virax Biolabs website address?

The website address for Virax Biolabs is viraxbiolabs.com

Which industry sector does Virax Biolabs operate in?

Virax Biolabs operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

Symbol	Price	Vol.
WHLRWheeler Real Estate Investment Trust Inc	$ 7.01 (104.97%)	45.92M
SSIISS Innovations International Inc	$ 8.6599 (77.46%)	2.45M
LUCYInnovative Eyewear Inc	$ 3.82 (67.54%)	73.98M
INLFINLIF Limited	$ 1.4206 (57.34%)	48.07M
GRRRGorilla Technology Group Inc	$ 26.29 (39.77%)	9.53M
NWGLNature Wood Group Ltd	$ 1.5894 (-71.77%)	3.02M
ICUSeaStar Medical Holding Corporation	$ 0.4712 (-51.74%)	1.71M
MBRXMoleculin Biotech Inc	$ 0.2942 (-49.54%)	10.33M
RGCRegencell Bioscience Holdings Ltd	$ 36.47 (-42.43%)	1.65M
RBNERobin Energy Ltd	$ 6.0398 (-30.82%)	3.9M
HCTIHealthcare Triangle Inc	$ 0.0297 (12.08%)	416.54M
DFLIDragonfly Energy Holdings Corporation	$ 0.2855 (30.96%)	299.95M
GNLNGreenlane Holdings Inc	$ 0.00915 (-11.59%)	184.23M
NVDANVIDIA Corporation	$ 143.95 (-1.05%)	122.96M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	$ 12.4601 (0.73%)	120.51M

Symbol

Price

Vol.

HCTIHealthcare Triangle Inc

$ 0.0297

(12.08%)

416.54M

DFLIDragonfly Energy Holdings Corporation

$ 0.2855

(30.96%)

299.95M

GNLNGreenlane Holdings Inc

$ 0.00915

(-11.59%)

184.23M

NVDANVIDIA Corporation

$ 143.95

(-1.05%)

122.96M

TSLLDirexion Daily TSLA Bull 2X Trust ETF

$ 12.4601

(0.73%)

120.51M

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Virax Biolabs Group Ltd (VRAX) Quote

Virax Biolabs Group Ltd (VRAX)

Professional-Grade Tools, for Individual Investors.

Key stats and details

About Virax Biolabs Group Ltd

Ask ADVFN Intelligence (AI)

VRAX Latest News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs to Present at 19th World Immune Regulation Meeting

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs to Present at 19th World Immune Regulation Meeting

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

VRAX - Frequently Asked Questions (FAQ)

Movers

VRAX Discussion

Your Recent History

Company

Business

Popular

Get The App

Sign in

Go Ad-Free